-
Mashup Score: 0Clinicopathologic Characteristics and Prognostic Impact of Atypical EGFR Mutations in Patients With Completely Resected Lung Adenocarcinoma - 1 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Long-Term Outcomes Following Pembrolizumab vs Chemotherapy as First-Line Therapy in Patients With NSCLC With PD-L1 Tumor Proportion Score ≥1% - 1 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Durvalumab With or Without Tremelimumab Plus Chemotherapy as First-Line Therapy for Metastatic NSCLC - 1 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Long-Term Survival Outcomes With Nivolumab Plus Ipilimumab vs Chemotherapy as First-Line Treatment for Metastatic NSCLC - 1 year(s) ago
Written by Jean-Yves Douillard MD, PhD
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer - 2 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ESMO Clinical Practice Guideline for the Diagnosis and Management of Toxicities From Immunotherapy - 2 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Written by Michael J. Grant MD
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Osimertinib Plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Patients With EGFR–Mutated MET-Amplified NSCLC - 2 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Clinicopathologic Characteristics and Prognostic Impact of Atypical EGFR Mutations in Patients With Completely Resected Lung Adenocarcinoma https://t.co/5PvVl2tYri #lcsm #lungcancer